title: Retinal break and rhegmatogenous retinal detachment after transpupillary thermotherapy as primary or adjunct treatment of choroidal melanoma.
abstract: OBJECTIVE
  To report the development of retinal break or rhegmatogenous retinal detachment (RRD) after transpupillary thermotherapy (TTT) as primary or adjunct treatment of choroidal melanoma.
  
  
  METHODS
  In this noncomparative, interventional case series, the authors reviewed medical records of 13 patients who developed retinal break or RRD following TTT. The main outcome measures were clinical features and outcome of treatment of retinal break or RRD following TTT.
  
  
  RESULTS
  Of 1574 patients managed on the Oncology Service at Wills Eye Institute with TTT as primary or adjunct treatment of choroidal melanoma, 13 (1%) developed retinal break with or without RRD. The mean patient age at diagnosis of choroidal melanoma was 56 years. Treatment for choroidal melanoma included combined plaque radiotherapy and TTT in 10 patients and TTT alone in 3 patients. The median number of TTT sessions before development of retinal break or RRD was 2. Retinal break or RRD developed at a median of 3 months following the last TTT. All the retinal breaks were located in the TTT-treated area. Retinal breaks were atrophic in 11 eyes and horseshoe shaped in 2 cases. The extent of retinal detachment was none in 1 eye, 1 quadrant or less in 5 eyes, 2 or 3 quadrants in 4 eyes, and 4 quadrants in 3 eyes. Seven patients underwent vitrectomy, one received cryotherapy and laser photocoagulation, and five were observed without treatment. In all eight patients who received treatment for RRD, the retina was attached after a mean follow-up period of 54 months with no intraocular or local extraocular tumor dissemination.
  
  
  CONCLUSIONS
  Development of retinal break or RRD is a rare complication of TTT for treatment of choroidal melanoma. The majority of these cases develop within 6 months of TTT and most are caused by atrophic retinal holes in the TTT-treated area.
authors.affiliation: Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, PA 19107, USA. arman_mash@yahoo.com
authors.forename: Arman
authors.initials: A
authors.lastname: Mashayekhi
authors.forename: Carol L
authors.initials: CL
authors.lastname: Shields
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Lee
authors.forename: Brian P
authors.initials: BP
authors.lastname: Marr
authors.forename: Jerry A
authors.initials: JA
authors.lastname: Shields
mesh_terms: D000328:Adult; D000368:Aged; D001918:Brachytherapy; D002830:Choroid Neoplasms / Q000628:therapy*; D003131:Combined Modality Therapy; D017679:Cryotherapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects*; D017075:Laser Coagulation; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D011680:Pupil; D012163:Retinal Detachment / Q000000981:diagnostic imaging / Q000209:etiology* / Q000601:surgery; D012167:Retinal Perforations / Q000000981:diagnostic imaging / Q000209:etiology* / Q000601:surgery; D041623:Tomography, Optical Coherence; D014463:Ultrasonography; D014821:Vitrectomy